Maynard Um
-
-
-
-
-
-
-
Veru reports fiscal 2025 results, plans obesity drug trial
-
-
-
-
-
-
-
Veru, Inc. (VERU) Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Veru, Inc. (VERU) as Key Catalyst Approaches
-
-
-
-
-
-
-
Veru, Inc. (VERU) PT Lowered to $1 at Jefferies
396,356 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

